UNEARNED REVENUE	6 Months Ended
Jun. 30, 2026
Revenue Recognition and Deferred Revenue [Abstract]
UNEARNED REVENUE	Note 7. UNEARNED REVENUE The Company engaged in an observational study of CyPath^® Lung with the Department of War. A total of 70 CyPath^® Lung units were ordered and shipped. However, in compliance with FASB ASC 606, the performance obligation was complete for only 43 units as of June 30, 2026. The performance obligation is deemed complete after samples have been collected and processed and results analyzed. The unearned revenue balance amounted to $22,696 and $23,827 as of June 30, 2026, and December 31, 2025, respectively. During August 2025, the Company engaged with Veterans Administration (“VA”) medical centers to purchase CyPath^®Lung tests. A total of 30 tests were ordered and shipped. However, in compliance with FASB ASC 606, the performance obligation was complete for 20 tests as of June 30, 2026. The performance obligation is deemed complete after samples have been collected, processed, and analyzed and results communicated to patients. The unearned revenue balance amounted to $8,444 and $18,578 as of June 30, 2026 and December 31, 2025, respectively.

UNEARNED REVENUE

6 Months Ended

Jun. 30, 2026

Revenue Recognition and Deferred Revenue [Abstract]

Note 7. UNEARNED REVENUE

The Company engaged in an observational study of CyPath^® Lung with the Department of War. A total of 70 CyPath^® Lung units were ordered and shipped. However, in compliance with FASB ASC 606, the performance obligation was complete for only 43 units as of June 30, 2026. The performance obligation is deemed complete after samples have been collected and processed and results analyzed. The unearned revenue balance amounted to $22,696 and $23,827 as of June 30, 2026, and December 31, 2025, respectively.

During August 2025, the Company engaged with Veterans Administration (“VA”) medical centers to purchase CyPath^®Lung tests. A total of 30 tests were ordered and shipped. However, in compliance with FASB ASC 606, the performance obligation was complete for 20 tests as of June 30, 2026. The performance obligation is deemed complete after samples have been collected, processed, and analyzed and results communicated to patients. The unearned revenue balance amounted to $8,444 and $18,578 as of June 30, 2026 and December 31, 2025, respectively.